NLS Pharmaceutics (NLSP) has released an update.
Kadimastem Ltd. faces significant financial challenges as its recent audit reveals recurring losses and a negative cash flow, casting doubt on its ability to continue as a viable entity. The company’s financial statements, although in compliance with IFRS, highlight a deficiency in equity and working capital, raising concerns among investors about its future sustainability.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.
